AstraZeneca: good set of numbers, shares advance.

(CercleFinance.com) - AstraZeneca's product sales fell by 9% over the first nine months of 2017, impacted by losses of exclusivity on its anti-cholesterol drug Crestor and antipsychotic drug Seroquel XR.

Year-to-date sales decreased from 16.05 billion dollars to 14.66 billion dollars, the drugmaker said on Thursday.